Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 11,000 | |||
25 mg | 在庫あり | ¥ 22,500 | |||
50 mg | 在庫あり | ¥ 34,000 | |||
100 mg | 在庫あり | ¥ 54,500 | |||
500 mg | 在庫あり | ¥ 134,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 7,000 |
説明 | CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days. |
ターゲット&IC50 | SRE.L:0.64 μM |
別名 | CCG203971 |
分子量 | 408.88 |
分子式 | C23H21ClN2O3 |
CAS No. | 1443437-74-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 73 mg/mL(178.5 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG-203971 1443437-74-8 Cell Cycle/Checkpoint GPCR/G Protein MAPK Rho Ras CCG 203971 Inhibitor SRF MKL1 inhibit MRTF anti-metastasis PC-3 CCG203971 migration inhibitor